Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703196 · ClinicalTrials.gov registry record · Phase 2
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
A Phase 2 study of Cervical Cancer and Precancerous Condition, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 368
- Enrollment target
- 1
- Study location
NCT00703196 is a Phase 2 study of Cervical Cancer and Precancerous Condition that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 368 participants, below the 568-participant average among 144 other Cervical Cancer trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00703196, a Phase 2 study of Cervical Cancer and Precancerous Condition, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 368 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Supplements, such as folic acid, may stop or delay the development of cervical cancer in women infected with human papillomavirus. PURPOSE: This phase II trial is studying how well folic acid supplements work in preventing cancer in women infected with human papillomavirus.
Conditions Studied
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT folic acid
Study Locations (1)
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00703196
The ClinicalTrials.gov registry entry for NCT00703196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 568-participant average among 144 other Cervical Cancer trials with a reported enrollment target (35% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00703196 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00703196 about?
NCT00703196 is a clinical study titled "Folic Acid Clinical Trial for the Prevention of Cervical Cancer". RATIONALE: Supplements, such as folic acid, may stop or delay the development of cervical cancer in women infected with human papillomavirus. PURPOSE: This phase II trial is studying how well folic acid supplements work in preventing cancer in women infected with human papillomavirus.
What is the current status of trial NCT00703196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 368 participants. The study started on 2007-03.
What conditions does trial NCT00703196 study?
This clinical trial studies the following conditions: Cervical Cancer, Precancerous Condition.
What interventions are being tested in trial NCT00703196?
The interventions under investigation include: placebo (OTHER), folic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00703196?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00703196 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.